Teva Acquires Emalex for $700M with Up to $200M Milestones, Boosting Neuroscience Pipeline
TEVA•Teva paid $700 million upfront for Emalex Biosciences with up to $200 million in commercial milestone payments and net sales royalties. The deal adds ecopipam—an FDA Orphan Drug and Fast Track–designated D1 receptor antagonist with published Phase 3 Tourette syndrome data and an NDA planned in H2 2026.
1. Acquisition Details
Teva closed its acquisition of Emalex Biosciences for $700 million in upfront consideration, with potential for $200 million in commercial milestone payments plus net sales royalties upon regulatory approval and commercialization of ecopipam.
2. Ecopipam Profile and Data
Ecopipam is a first-in-class selective dopamine D1 receptor antagonist designated an FDA Orphan Drug and Fast Track therapy for pediatric Tourette syndrome; Phase 3 results showed a statistically significant delay to relapse (p=0.0084) and a tolerable safety profile.
3. Regulatory and Commercial Timeline
Teva anticipates submitting a U.S. NDA for ecopipam in the second half of 2026, positioning the company to leverage late-stage data and potential market exclusivity under Orphan Drug status.
4. Strategic Impact
This transaction aligns with Teva’s Pivot to Growth initiative by deepening its late-stage neuroscience pipeline, targeting an area of high unmet need and supporting near- and long-term revenue expansion.
